menu
    • menu
    [{"orgOrder":0,"company":"Apotex Inc","sponsor":"CHIESI USA INC","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Small molecule","year":"2020","type":"Acquisition","leadProduct":"Deferiprone","moa":"Iron","graph1":"Genetic Disease","graph2":"Approved","graph3":"Apotex Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Apotex Inc \/ Chiesi Group","highestDevelopmentStatusID":"12","companyTruncated":"Apotex Inc \/ Chiesi Group"},{"orgOrder":0,"company":"Apotex Inc","sponsor":"ProvideGx","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Partnership","leadProduct":"Cefazolin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Apotex Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"injection","sponsorNew":"Apotex Inc \/ ProvideGx","highestDevelopmentStatusID":"12","companyTruncated":"Apotex Inc \/ ProvideGx"},{"orgOrder":0,"company":"Apotex Inc","sponsor":"RedHill Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Naloxegol Oxalate","moa":"Mu-opioid receptor","graph1":"Gastroenterology","graph2":"Approved","graph3":"Apotex Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Apotex Inc \/ Apotex","highestDevelopmentStatusID":"12","companyTruncated":"Apotex Inc \/ Apotex"},{"orgOrder":0,"company":"Apotex Fermentation Inc.","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Brimonidine Tartrate","moa":"Adrenergic receptor alpha-2","graph1":"Ophthalmology","graph2":"Approved","graph3":"Apotex Fermentation Inc.","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Apotex Fermentation Inc. \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Apotex Fermentation Inc. \/ Not Applicable"},{"orgOrder":0,"company":"Apotex Fermentation Inc.","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Aciclovir","moa":"DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Apotex Fermentation Inc.","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Apotex Fermentation Inc. \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Apotex Fermentation Inc. \/ Not Applicable"},{"orgOrder":0,"company":"Apotex Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Bendamustine Hydrochloride","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Apotex Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Apotex Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Apotex Inc \/ Not Applicable"},{"orgOrder":0,"company":"Apotex Fermentation Inc.","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Paclitaxel","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Apotex Fermentation Inc.","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Apotex Fermentation Inc. \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Apotex Fermentation Inc. \/ Not Applicable"},{"orgOrder":0,"company":"Apotex Inc","sponsor":"Harrow","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Cyclosporine","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Apotex Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"Apotex Inc \/ Apotex Inc.","highestDevelopmentStatusID":"12","companyTruncated":"Apotex Inc \/ Apotex Inc."},{"orgOrder":0,"company":"Apotex Inc","sponsor":"SEARCHLIGHT PHARMA INC","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Tretinoin","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Apotex Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Apotex Inc \/ Apotex Inc","highestDevelopmentStatusID":"12","companyTruncated":"Apotex Inc \/ Apotex Inc"},{"orgOrder":0,"company":"Apotex Fermentation Inc.","sponsor":"Ambio","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Teriparatide","moa":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Apotex Fermentation Inc.","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Apotex Fermentation Inc. \/ Ambio","highestDevelopmentStatusID":"12","companyTruncated":"Apotex Fermentation Inc. \/ Ambio"},{"orgOrder":0,"company":"Apotex Inc","sponsor":"SEARCHLIGHT PHARMA INC","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Tretinoin","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Apotex Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Apotex Inc \/ Apotex Inc","highestDevelopmentStatusID":"12","companyTruncated":"Apotex Inc \/ Apotex Inc"},{"orgOrder":0,"company":"Apotex Fermentation Inc.","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Cetrorelix Acetate","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Apotex Fermentation Inc.","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"","sponsorNew":"Apotex Fermentation Inc. \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Apotex Fermentation Inc. \/ Not Applicable"},{"orgOrder":0,"company":"Apotex Inc","sponsor":"Formosa Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Clobetasol Propionate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Apotex Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Apotex Inc \/ Apotex Inc","highestDevelopmentStatusID":"14","companyTruncated":"Apotex Inc \/ Apotex Inc"},{"orgOrder":0,"company":"Apotex Fermentation Inc.","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Dasatinib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Apotex Fermentation Inc.","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Apotex Fermentation Inc. \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Apotex Fermentation Inc. \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Apotex Inc

    Menu

    Apotex Inc

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    EXCIPIENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Apotex Fermentation Inc.

                            Canada arrow
                            American Pharma Summit
                            Not Confirmed

                            Apotex Fermentation Inc.

                            Canada arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dasatinib

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Apotex Launches Generic Dasatinib Tablets in The U.S.

                            Details : Sprycel (dasatinib) is an oral film-coated tablet, a protein kinase inhibiting small molecule drug. It is indicated for the treatment of chronic myeloid leukemia.

                            Brand Name : Sprycel-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 04, 2024

                            Lead Product(s) : Dasatinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Apotex Inc

                            Canada arrow
                            American Pharma Summit
                            Not Confirmed

                            Apotex Inc

                            Canada arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clobetasol Propionate

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Recipient : Formosa Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Formosa Pharmaceuticals Announce Licensing Agreement with Apotex for Clobetasol Propionate

                            Details : Through the licensing agreement, Apotex will gain exclusive rights of APP13007 (clobetasol propionatei) in Canada for commercialization to treat inflammation and pain following ocular surgery.

                            Brand Name : APP13007

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 05, 2024

                            Lead Product(s) : Clobetasol Propionate

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Recipient : Formosa Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Apotex Inc

                            Canada arrow
                            American Pharma Summit
                            Not Confirmed

                            Apotex Inc

                            Canada arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tretinoin,Benzoyl Peroxide

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Recipient : SEARCHLIGHT PHARMA INC

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Apotex Acquires Searchlight, a Canadian Specialty Innovative Branded Pharma Company

                            Details : Apotex will commercialize Twyneo (tretinoin), a retinoic acid receptor agonist in combination with Benzoyl Peroxide indicated for the topical treatment of acne vulgaris.

                            Brand Name : Twyneo

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 03, 2024

                            Lead Product(s) : Tretinoin,Benzoyl Peroxide

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Recipient : SEARCHLIGHT PHARMA INC

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Apotex Fermentation Inc.

                            Canada arrow
                            American Pharma Summit
                            Not Confirmed

                            Apotex Fermentation Inc.

                            Canada arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cetrorelix Acetate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Apotex Corp. Launches Generic Fertility Treatment Injectable Cetrorelix® in the US

                            Details : Cetrorelix Acetate for Injection is a synthetic decapeptide with GnRH antagonist, indicated for the inhibition of premature LH surges in women undergoing controlled ovarian stimulation.

                            Brand Name : Cetrotide-Generic

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            May 14, 2024

                            Lead Product(s) : Cetrorelix Acetate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Apotex Inc

                            Canada arrow
                            American Pharma Summit
                            Not Confirmed

                            Apotex Inc

                            Canada arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tretinoin,Benzoyl Peroxide

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Recipient : SEARCHLIGHT PHARMA INC

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Apotex to Acquire Searchlight Pharma, a Canadian Specialty Branded Pharmaceutical Leader

                            Details : Through acquisition, Apotex will commercialize Twyneo (tretinoin), a retinoic acid receptor agonist combined with Benzoyl Peroxide for treating acne vulgaris in patients aged 9 and older.

                            Brand Name : Twyneo

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 02, 2024

                            Lead Product(s) : Tretinoin,Benzoyl Peroxide

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Recipient : SEARCHLIGHT PHARMA INC

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Apotex Inc

                            Canada arrow
                            American Pharma Summit
                            Not Confirmed

                            Apotex Inc

                            Canada arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cyclosporine

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Recipient : Harrow

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Harrow Licenses Canadian Rights to Apotex for Five Ophthalmic Products

                            Details : Through a licensing agreement, Apotex will market Verkazia (cyclosporine) ophthalmic emulsion, a calcineurin inhibitor indicated for treating vernal keratoconjunctivitis in children and adults.

                            Brand Name : Verkazia

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 15, 2024

                            Lead Product(s) : Cyclosporine

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Recipient : Harrow

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Apotex Fermentation Inc.

                            Canada arrow
                            American Pharma Summit
                            Not Confirmed

                            Apotex Fermentation Inc.

                            Canada arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Teriparatide

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Approved

                            Sponsor : Ambio

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Apotex Corp. Launches Teriparatide Injectable for Osteoporosis Treatment in the United States

                            Details : Teriparatide Injection, a single-patient-use pre-filled pen and a parathyroid hormone analog, is used for the treatment of osteoporosis in the United States.

                            Brand Name : Teriparatide-Generic

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            November 21, 2023

                            Lead Product(s) : Teriparatide

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Approved

                            Sponsor : Ambio

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Apotex Inc

                            Canada arrow
                            American Pharma Summit
                            Not Confirmed

                            Apotex Inc

                            Canada arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bendamustine Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Apotex Corp. Launches Bendamustine Hydrochloride Injection in the United States

                            Details : Bendamustine hydrochloride is a bifunctional mechlorethamine derivative containing a purine-like benzimidazole ring, which can lead to cell death via several pathways. It is active against both quiescent and dividing cells.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 26, 2023

                            Lead Product(s) : Bendamustine Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Apotex Fermentation Inc.

                            Canada arrow
                            American Pharma Summit
                            Not Confirmed

                            Apotex Fermentation Inc.

                            Canada arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aciclovir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Advisory - Apotex Recalls Apo-Acyclovir Tablets Due to a Nitrosamine Impurity

                            Details : Apotex Inc. is recalling certain lots of Apo-Acyclovir (acyclovir) tablets, in 200 mg and 800 mg strengths, due to the presence of a nitrosamine impurity (N-nitrosodimethylamine [NDMA]) above the acceptable level.

                            Brand Name : Apo-Acyclovir

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 28, 2022

                            Lead Product(s) : Aciclovir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Apotex Fermentation Inc.

                            Canada arrow
                            American Pharma Summit
                            Not Confirmed

                            Apotex Fermentation Inc.

                            Canada arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Paclitaxel

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Apotex Corp. Launches Generic of Abraxane in the United States

                            Details : Paclitaxel is a intravenously injectable, non-Cremophor based formulation of paclitaxel, which is used to treat breast, ovarian, lung, bladder, prostate, melanoma, and esophageal cancer, as well as other types of solid tumor cancer.

                            Brand Name : Abraxane-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 12, 2022

                            Lead Product(s) : Paclitaxel

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth